LITMIR.BIZ

Скачать книгу

about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.

      20. Kassirer J. P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

      21. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.

      22. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.

      23. Gøtzsche P. C. Big pharma often commits corporate crime, and this must be stopped. BMJ. 2012; 345: e8462.

      24. Gøtzsche P. C. Corporate crime in the pharmaceutical industry is common, serious and repetitive. Available online at: www.cochrane.dk/research/corporatecrime/Corporate-crime-long-version.pdf (accessed 20 December 2012).

      25. Pfizer agrees record fraud fine. BBC News. 2009 Sept 2.

      26. Tanne J. H. Pfizer pays record fi ne for off-label promotion of four drugs. BMJ. 2009; 339: b3657.

      27. Evans D. Big pharma’s crime spree. Bloomberg Markets. 2009 Dec: 72–86.

      28. United States Department of Justice. Novartis Pharmaceuticals Corp. to Pay More than $420 million to Resolve Off-Label Promotion and Kickback Allegations. 2010 Sept 30.

      29. SourceWatch. Sanofi – Aventis. 2011 Jan 23. Available online at: www.sourcewatch.org/index.phptitle=Sanofi – Aventis (accessed 19 June 2012).

      30. Aventis to pay $95 million to settle fraud charge. AFP. 2009 May 28.

      31. Rabiner S. Glaxo $3B fi ne largest healthcare fraud settlement in history? FindLaw. 2011 Nov 10.

      32. United States Department of Justice. GlaxoSmithKline to Plead Guilty and Pay $3 billion to Resolve Fraud Allegations and Failure to Report Safety Data. 2012 July 2.

      33. Thomas K., Schmidt M. S. Glaxo agrees to pay $3 billion in fraud settlement. New York Times. 2012 July 2.

      34. Wilson D. Ex-Glaxo executive is charged in drug fraud. New York Times. 2010 Nov 9.

      35. Khan H., Thomas P. Drug giant AstraZeneca to pay $520 million to settle fraud case. ABC News. 2010 April 27.

      36. Tanne J. H. AstraZeneca pays $520m fi ne for off-label marketing. BMJ. 2010; 340: c2380.

      37. Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. BMJ. 2009; 339: b5164.

      38. Cohen D. Complications: tracking down the data on oseltamivir. BMJ. 2009; 339: b5387.

      39. Cohen D., Carter P. WHO and the pandemic flu ‘conspiracies’. BMJ. 2012; 340: c2912.

      40. Willman D. Relenza: official asks if one day less of flu is worth it. Los Angeles Times. 2000 Dec 20.

      41. Epstein H. Flu warning: beware the drug companies! New York Review of Books. 2001 Apr 11.

      42. Jefferson T., Jones M. A., Doshi P., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2012; 1: CD008965.

      43. Rennie D. Guarding the guardians: a conference on editorial peer review. JAMA. 1986; 256: 2391–2.

      44. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012; 9: e1001201.

      45. O’Dowd A. Response to swine flu was ‘unjustified’, says Council of Europe. BMJ. 2012; 340: c3033.

      46. Gøtzsche P. C. European governments should sue Roche and prescribers should boycott its drugs. BMJ. 2012; 345: e7689.

      47. Cohen D. Search for evidence goes on. BMJ. 2012; 344: e458.

      48. Ark. judge fines Johnson & Johnson more than $1.1B in Risperdal case. CBS/AP. 2012 April 11.

      49. Harris G. Research center tied to drug company. New York Times. 2008 Nov 25.

      50. Kelton E. J&J needs a cure: new CEO allegedly had links to fraud. Forbes. 2012 17 April.

      51. Silverman E. Merck to pay $670 million over Medicaid fraud. Pharmalot. 2008 Feb 7.

      52. Reuters. The largest pharma fraud whistleblower case in U. S. history totaling $14 billion. 2009 Jan 15.

      53. Anonymous. Abbott Labs to pay $15. billion more for Medicaid fraud. 2012 May 8. Available online at: http://somd.com/news/headlines/2012/15451.shtml (accessed 19 June 2012).

      54. Roehr B. Abbott pays $1.6bn for promoting off label use of valproic acid. BMJ. 2012; 344: e3343.

      55. Barnes K. Sanofi slammed by FDA over failure to act on Ketek fraud. Outsourcing. 2007 Oct 25.

      56. Ross D. B. The FDA and the case of Ketek. N Engl J Med. 2007; 356: 1601–4.

      57. Soreth J., Cox E., Kweder S., et al. Ketek – the FDA perspective. N Engl J Med. 2007; 356:1675–6.

      58. Ketek Official FDA information, side effects and uses. Available online at: www.drugs.com/pro/ketek.html (accessed 18 Nov 2012).

      59. Russell J. Johnson & Johnson feels pain of $75m bribery fines. The Telegraph. 2011 9 April.

      60. Pringle E. Eli Lilly hides data: Zyprexa, Evista, Prozac risk. Conspiracy Planet. Available online at: www.conspiracyplanet.com/channel.cfm?channelid=55&contentid=4181&page=2 (accessed 28 June 2012).

      61. Clinard M. B., Yeager P. C. Corporate Crime. New Brunswick: Transaction Publishers; 2006.

      62. Harris G. As doctors write prescriptions, drug company writes a check. New York Times. 2004 June 27.

      63. Lane C. Bad medicine: GlaxoSmithKline’s fraud and gross negligence. Psychology Today. 2011 Jan 7.

      64. Silverman E. Glaxo to pay $750M for manufacturing fraud. Pharmalot. 2010 Oct 26.

      65. Wikipedia. GlaxoSmithKline. Available online at: http://en.wikipedia.org/wiki/GlaxoSmithKline (accessed 20 June 2012).

      66. Carpenter G. Italian doctors face charges over GSK incentive scheme. Over 4000 doctors are alleged to have received cash, gifts, and prizes to encourage them to prescribe GSK products. Lancet. 2004; 363: 1873.

      67. Company news; drug maker agrees to pay $175 million in lawsuit. New York Times. 2004 Feb 7.

      68. Prescription generics & patent management. Strategies in the Pharmaceutical Industry 2004. 2004 Nov 29.

      69. Relman A. S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.

      70. Jack A. Legal tactics to delay launch of generic drugs cost Europe Ђ3bn. BMJ. 2008; 337: 1311.

      71. Tanne J. H. Bristol-Myers Squibb made to pay $515 m to settle US law suits. BMJ. 2007; 335: 742–3.

      72. Anonymous. Bristol-Myers will settle antitrust charges by U. S. New York Times. 2003 March 8.

      73. Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.

      74. European Commission. Antitrust: Commission fines Lundbeck and other pharma companies for delaying market entry of generic medicines. Press release. 2013 June 19.

      75. Abelson R. Whistle-blower suit says device maker generously rewards doctors. New York Times. 2006 Jan 24.

      76. Poses R. M. Medtronic settles, yet again. Blog post. Health Care Renewal. 2011 Dec 15. Available online at: http://hcrenewal.blogspot.co.nz/2011/12/medtronic-settles-yet-again.html (accessed 10 July 2013).

      77. Tanne J. H. US companies are fined for payments to surgeons. BMJ. 2007; 335: 1065.

      78. Harris G., Pear R. Drug maker’s efforts to compete in lucrative insulin market are under scrutiny. New York

Скачать книгу